Abstract
The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.
| Original language | English |
|---|---|
| Journal | Journal of Human Hypertension |
| Volume | 10 |
| Issue number | SUPPL. 3 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Morbidity
- Mortality
- Nifedipine
- Outcome trial
- Thiazide
ASJC Scopus subject areas
- Internal Medicine
Cite this
INSIGHT : International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. / Brown, M. J.; Castaigne, A.; Ruilope, L. M.; Mancia, G.; Rosenthal, T.; De Leeuw, P. W.; Ebner, F.
In: Journal of Human Hypertension, Vol. 10, No. SUPPL. 3, 1996.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - INSIGHT
T2 - International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment
AU - Brown, M. J.
AU - Castaigne, A.
AU - Ruilope, L. M.
AU - Mancia, G.
AU - Rosenthal, T.
AU - De Leeuw, P. W.
AU - Ebner, F.
PY - 1996
Y1 - 1996
N2 - The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.
AB - The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.
KW - Morbidity
KW - Mortality
KW - Nifedipine
KW - Outcome trial
KW - Thiazide
UR - http://www.scopus.com/inward/record.url?scp=0029745614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029745614&partnerID=8YFLogxK
M3 - Article
C2 - 8872850
AN - SCOPUS:0029745614
VL - 10
JO - Journal of Human Hypertension
JF - Journal of Human Hypertension
SN - 0950-9240
IS - SUPPL. 3
ER -